drbob
  1. Benyamina, A. & Reynaud, M. [Therapeutic use of cannabis derivatives]. Rev Prat 64, 165-168 (2014).
  2. Qin, H. & Ruan, Z. H. The Role of Monoacylglycerol Lipase (MAGL) in the Cancer Progress. Cell Biochem Biophys (2014).
  3. Cipriano, M., Gouveia-Figueira, S., Persson, E., Nording, M. & Fowler, C. J. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes 7, 441 (2014).
  4. Morelli, M. B. et al. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type- 2. Int J Cancer 134, 2534-2546 (2014).
  5. Murase, R. et al. Targeting multiple cannabinoid antitumor pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol (2014).
  6. Moreno, E. et al. Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. J Biol Chem (2014).
  7. Georgakilas, A. G. et al. Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol. Cancer Lett 353, 248-257 (2014).
  8. Rocha, F. C., Dos Santos Junior, J. G., Stefano, S. C. & da Silveira, D. X. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol 116, 11-24 (2014).
  9. Hermanson, D. J., Gamble-George, J. C., Marnett, L. J. & Patel, S. Substrate- selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci (2014).
  10. Moreno-Sanz, G. et al. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. Pharmacol Res 87C, 87-93 (2014).
  11. Dong, W. et al. Simulation of Swanson’s Literature-Based Discovery: Anandamide Treatment Inhibits Growth of Gastric Cancer Cells In Vitro and In Silico. PLoS One 9, e100436 (2014).
  12. Nader, J. et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB receptors. Neuropharmacology (2014).
  13. Haggstrom, J. et al. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: A Bayesian network analysis of data from a tissue microarray. Prostate 74, 1107-1117 (2014).
  14. Giordano, D., Draves, K. E., Li, C., Hohl, T. M. & Clark, E. A. Nitric Oxide Regulates BAFF Expression and T Cell-Independent Antibody Responses. J Immunol (2014).
  15. Rahman, I. A., Tsuboi, K., Uyama, T. & Ueda, N. New players in the fatty acyl ethanolamide metabolism. Pharmacol Res (2014).
  16. Hu, W. R. et al. Monoacylglycerol lipase promotes metastases in nasopharyngeal
  17. carcinoma. Int J Clin Exp Pathol 7, 3704-3713 (2014).
  18. Bjorklund, E., Larsson, T. N., Jacobsson, S. O. & Fowler, C. J. Ketoconazole Inhibits the Cellular Uptake of Anandamide via Inhibition of FAAH at Pharmacologically Relevant Concentrations. PLoS One 9, e87542 (2014).
  19. Bar-Sela, G., Avisar, A., Batash, R. & Schaffer, M. Is the clinical use of cannabis by oncology patients advisable? Curr Med Chem 21, 1923-1930 (2014).
  20. Bjorklund, E., Blomqvist, A., Hedlin, J., Persson, E. & Fowler, C. J. Involvement of Fatty Acid amide hydrolase and Fatty Acid binding protein 5 in the uptake of anandamide by cell lines with different levels of Fatty Acid amide hydrolase expression: a pharmacological study. PLoS One 9, e103479 (2014).
  21. Bakali, E. et al. Human urothelial cell lines as potential models for studying cannabinoid and excitatory receptor interactions in the urinary bladder. Naunyn Schmiedebergs Arch Pharmacol (2014).
  22. Ravi, J., Sneh, A., Shilo, K., Nasser, M. W. & Ganju, R. K. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget (2014).
  23. Afzal, O. et al. Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors. Bioorg Med Chem Lett (2014).
  24. Kohnz, R. A. & Nomura, D. K. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. Chem Soc Rev (2014).
  25. Bluett, R. J. et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4, e408 (2014).
  26. Yang, L. et al. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int J Mol Sci 15, 13637-13648 (2014).
  27. Hasko, J. et al. CB2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. Int J Mol Sci 15, 8063-8074 (2014).
  28. Ramer, R., Fischer, S., Haustein, M., Manda, K. & Hinz, B. CANNABINOIDs INHIBIT angiogenic capacities of Endothelial cells via release of Tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochem Pharmacol (2014).
  29. Haustein, M., Ramer, R., Linnebacher, M., Manda, K. & Hinz, B. CANNABINOIDS INCREASE LUNG CANCER CELL LYSIS BY LYMPHOKINE-ACTIVATED KILLER CELLS VIA UPREGULATION OF ICAM-1. Biochem Pharmacol (2014).
  30. Davis, M. P. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs 1-18 (2014).
  31. Chakravarti, B., Ravi, J. & Ganju, R. K. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014).
  32. Messalli, E. M., Grauso, F., Luise, R., Angelini, A. & Rossiello, R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol (2014).
  33. Fukuda, S. et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord 15, 275 (2014).
  34. Park, S. W. et al. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species.Head Neck (2014).
  35. Picardi, P., Ciaglia, E., Proto, M. & Pisanti, S. Anandamide inhibits breast tumor- induced angiogenesis. Transl Med UniSa 10, 8-12 (2014).
  36. Sousa-Valente, J., Varga, A., Ananthan, K., Khajuria, A. & Nagy, I. Anandamide in primary sensory neurons: too much of a good thing? Eur J Neurosci 39, 409-418 (2014).
  37. Gomez, R. et al. Anandamide impairs cell growth and induces apoptosis in chondrocytes. J Orthop Res (2014).
  38. Masoodi, M. et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. Leukemia (2014).
  39. Pacher, P. Towards the use of non-psychoactive cannabinoids for prostate cancer. Br J Pharmacol 168, 76-78 (2013).
  40. Robson, P. J. Therapeutic potential of cannabinoid medicines. Drug Test Anal (2013).
  41. Hazekamp, A. & Heerdink, E. R. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol (2013).
  42. Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C. & Bifulco, M. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci (2013).
  43. Karasu, T. et al. The Effect of Mifepristone (RU486) on the Endocannabinoid System in Human Plasma and First Trimester Trophoblast of Women undergoing Termination of Pregnancy. J Clin Endocrinol Metab jc20132922 (2013).
  44. Sharkey, K. A., Darmani, N. A. & Parker, L. A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol (2013).
  45. Zhang, L. P., Ma, F., Abshire, S. M. & Westlund, K. N. Prolonged High Fat / Alcohol Exposure Increases TRPV4 and Its Functional Responses in Pancreatic Stellate Cells. Am J Physiol Regul Integr Comp Physiol (2013).
  46. Matos, I., Bento, A. F., Marcon, R., Claudino, R. F. & Calixto, J. B. Preventive and therapeutic oral administration of the pentacyclic triterpene alpha,beta-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. Mol Immunol 54, 482-492 (2013).
  47. Cheng, J. et al. Potential role of CYP2D6 in the central nervous system. Xenobiotica (2013).
  48. Pezuk, J. A. et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Ther 20, 499- 506 (2013).
  49. Gebeh, A. K., Willets, J. M., Marczylo, T. H. & Konje, J. C. Plasma Anandamide and Related N-acylethanolamide Levels are not Elevated in Pregnancies Complicated by Hyperemesis Gravidarum. J Matern Fetal Neonatal Med (2013).
  50. Aaltonen, N. et al. Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem Biol 20, 379-390 (2013).
  51. Tanasescu, R. & Constantinescu, C. S. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol (2013).
  52. Chew, S. C. et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients. Eur J Clin Pharmacol (2013).
  53. Gangemi, G. et al. PBOX-15 induces apoptosis and improves the efficacy of

  54. oxaliplatin in human colorectal cancer cell lines. Eur J Pharmacol 714, 379-387(2013).
  55. Keimpema, E. et al. Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. Proc Natl Acad Sci U S A (2013).
  56. Lang, U. E. & Borgwardt, S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem 31, 761-777 (2013).
  57. Kapoor, S. Modulation of intracellular pathways by anandamide and its evolving role in oncology. Eur J Cancer (2013).
  58. Ueda, N., Tsuboi, K. & Uyama, T. Metabolism of endocannabinoids and related N- acylethanolamines: Canonical and alternative pathways. FEBS J (2013).
  59. Callaghan, R. C., Allebeck, P. & Sidorchuk, A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 24, 1811-1820 (2013).
  60. Hernan Perez de la Ossa, D. et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One 8, e54795 (2013).
  61. Uyama, T. et al. Involvement of phospholipase A/acyltransferase-1 in N- acylphosphatidylethanolamine generation. Biochim Biophys Acta (2013).
  62. De Chiara, V. et al. Interleukin-1beta alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. Neuroscience 250, 232-239 (2013).
  63. Li, H. et al. Inhibition Of Fatty Acid Amide Hydrolase Activates Nrf2 Signaling And Induces Heme Oxygenase 1 Transcription In Breast Cancer Cells. Br J Pharmacol (2013).
  64. Romano, B. et al. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine (2013).
  65. Bilmin, K., Kopczynska, B. & Grieb, P. Influence of serum and albumin on the in vitro anandamide cytotoxicity toward C6 glioma cells assessed by the MTT cell viability assay: implications for the methodology of the MTT tests. Folia Neuropathol 51, 44-50 (2013).
  66. Khasabova, I. A. et al. Increased Anandamide Uptake by Sensory Neurons Contributes to Hyperalgesia in a Model of Cancer Pain. Neurobiol Dis (2013).
  67. Kotsikorou, E. et al. Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High Potency GPR55 Selective Ligands. Biochemistry (2013).
  68. Khan, K. A. et al. HIV-1 Nef Interacts with HCV Core, Recruits TRAF2, TRAF5 and TRAF6, and Stimulates HIV-1 Replication in Macrophages. J Innate Immun (2013).
  69. Shubbar, E. et al. High levels of gamma-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC Cancer 13, 47 (2013).
  70. Wu, C. S. et al. GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. PLoS One 8, e60314 (2013).
  71. Gebeh, A. K. et al. Elevated Anandamide and Related N-Acylethanolamine Levels Occur in the Peripheral Blood of Women With Ectopic Pregnancy and Are Mirrored by Changes in Peripheral Fatty Acid Amide Hydrolase Activity. J ClinEndocrinol Metab (2013).
  72. Tashkin, D. P. Effects of marijuana smoking on the lung. Ann Am Thorac Soc 10, 239-247 (2013).
  73. Gustafsson, S. B. et al. Effects of cannabinoids and related fatty acids upon the viability of P19 embryonal carcinoma cells. Arch Toxicol (2013).
  74. Rimmerman, N. et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis 4, e949 (2013).
  75. Repossi, G., Pasqualini, M. E., Das, U. N. & Eynard, A. R. Differential Modulation of Tumor Cell Proliferation and their Endocannabinoid System by Polyunsaturated Fatty Acids. Curr Pharm Des (2013).
  76. Hecht, M. et al. Cytotoxic effect of Efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS (2013).
  77. Paul, A. G., Chandran, B. & Sharma-Walia, N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi’s sarcoma- associated herpes virus associated malignancies. Transl Res 162, 77-92 (2013).
  78. Cazade, M. et al. Cross Modulation and Molecular Interaction at the Cav3.3 Protein between the Endogenous Lipids and the T-type Calcium Channel Antagonist TTA- A2. Mol Pharmacol (2013).
  79. Cridge, B. J. & Rosengren, R. J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 5, 301-313 (2013).
  80. El Amrani, L. et al. CHANGES ON METABOLIC PARAMETERS INDUCED BY ACUTE CANNABINOID ADMINISTRATION (CBD, THC) IN A RAT EXPERIMENTAL MODEL OF NUTRITIONAL VITAMIN A DEFICIENCY. Nutr Hosp 28, 857-867 (2013).
  81. Prather, P. L. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun 441, 339-343 (2013).
  82. Hazekamp, A. & Romano, A. Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 1, 1-11 (2013).
  83. Naftali, T. et al. Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study. Clin Gastroenterol Hepatol (2013).
  84. Behrend, S. W. Cannabinoids may be therapeutic in breast cancer. Oncol Nurs Forum 40, 191-192 (2013).
  85. Ellert-Miklaszewska, A., Ciechomska, I. & Kaminska, B. Cannabinoid signaling in glioma cells. Adv Exp Med Biol 986, 209-220 (2013).
  86. Duff, G. et al. Cannabinoid Receptor CB2 Modulates Axon Guidance. PLoS One 8, e70849 (2013).
  87. Solinas, M. et al. Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect. PLoS One 8, e76918 (2013).
  88. Ward, S. J., McAllister, S. D., Neelakantan, H. & Walker, E. A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol (2013).
  89. Feinshtein, V. et al. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol (2013).
  90. Feinshtein, V. et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ 1, e153 (2013).
  91. Rempel, V. et al. Antagonists for the orphan G protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem (2013).
  92. Varga, A. et al. Anandamide produced by Ca-insensitive enzymes induces excitation in primary sensory neurons. Pflugers Arch (2013).
  93. Amoako, A. A. et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod (2013).
  94. Laezza, C., d’Alessandro, A., Malfitano, A. M. & Bifulco, M. Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer 49(8), 2066-2067 (2013).
  95. Fowler, C. J. et al. Tumour epithelial expression levels of endocannabinoid markers modulates the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. Biochim Biophys Acta (2012).
  96. Mulvihill, M. M. & Nomura, D. K. Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. Life Sci (2012).
  97. Idris, A. I. The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. Bonekey Rep 1, 224 (2012).
  98. Murphy, N. et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti- inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J Neuroinflammation 9, 79 (2012).
  99. Gamage, T. F. & Lichtman, A. H. The endocannabinoid system: role in energy regulation. Pediatr Blood Cancer 58, 144-148 (2012).
  100. Hamtiaux, L. et al. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer 12, 92 (2012).
  101. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367, 3353-3363 (2012).
  102. Pellei, M. et al. Synthesis and Biological Activity of Ester- and Amide- Functionalized Imidazolium Salts and Related Water-Soluble Coinage Metal N- Heterocyclic Carbene Complexes. Inorg Chem (2012).
  103. Windsor, M. A. et al. Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. ACS Med Chem Lett 3, 759- 763 (2012).
  104. Zhou, L. et al. Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography- Mass Spectrometry. J Proteome Res (2012).
  105. Grimaldi, C. & Capasso, A. Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids. Mini Rev Med Chem (2012).
  106. Idris, A. I. & Ralston, S. H. Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) 3, 136 (2012).
  107. Van Dross, R., Soliman, E., Jha, S., Johnson, T. & Mukhopadhyay, S. Receptor- dependent and Receptor-independent Endocannabinoid Signaling: A Therapeutic Target for Regulation of Cancer Growth. Life Sci (2012).
  108. Manera, C. et al. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8- naphthyridin-2(1H)-one scaffold. Eur J Med Chem 52, 284-294 (2012).
  109. Lacson, J. C. et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer (2012).
  110. Hernan Perez de la Ossa, D. et al. Poly-epsilon-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. J Control Release 161, 927-932 (2012).
  111. Klumpers, L. E. et al. Novel Delta(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 74, 42-53 (2012).
  112. 110. Vargas-Inchaustegui, D. A., Xiao, P., Tuero, I., Patterson, L. J. & Robert-Guroff, M. NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol 189, 1878-1885 (2012).
  113. Fowler, D. W., Copier, J., Wilson, N., Dalgleish, A. G. & Bodman-Smith, M. D. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 61, 535-547 (2012).
  114. Fowler, C. J. Monoacylglycerol lipase-a target for drug development? Br J Pharmacol (2012).
  115. Zhang, B. et al. Mitochondria Distinguish Granule-Stored from de novo Synthesized Tumor Necrosis Factor Secretion in Human Mast Cells. Int Arch Allergy Immunol 159, 23-32 (2012).
  116. Rubinsztein, D. C., Shpilka, T. & Elazar, Z. Mechanisms of autophagosome biogenesis. Curr Biol 22, R29-R34 (2012).
  117. Stanley, C. P., Hind, W. H. & O’Sullivan, S. E. Is the cardiovascular system a therapeutic target for CBD? Br J Clin Pharmacol (2012).
  118. Wilkerson, J. L. et al. Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain (2012).
  119. Amoako, A. A. et al. Impact of reference gene selection for type 2 cannabinoid receptor gene expression studies in human spermatozoa. Andrologia (2012).
  120. Zhao, P. & Abood, M. E. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci (2012).
  121. Uyama, T. et al. Generation of N-Acylphosphatidylethanolamine by Members of the Phospholipase A/Acyltransferase (PLA/AT) Family. J Biol Chem (2012).
  122. Lenglet, S. et al. Fatty Acid Amide Hydrolase Deficiency Enhances Intraplaque Neutrophil Recruitment in Atherosclerotic Mice. Arterioscler Thromb Vasc Biol (2012).
  123. Peterfi, Z. et al. Endocannabinoid-mediated long-term depression of afferent excitatory synapses in hippocampal pyramidal cells and GABAergic interneurons. J
  124. Neurosci 32, 14448-14463 (2012).
  125. Rani Sagar, D., Burston, J. J., Woodhams, S. G. & Chapman, V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 367, 3300-3311 (2012).
  126. Hsu, K. L. et al. DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol (2012).
  127. Killian, P. H. et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 33, 2507-2519 (2012).
  128. Engeli, S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 209, 357-381 (2012).
  129. Arnold, J. C., Hone, P., Holland, M. L. & Allen, J. D. CB(2) and TRPV(1) receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep 64, 751-757 (2012).
  130. Sagredo, O., Pazos, M. R., Valdeolivas, S. & Fernandez-Ruiz, J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov 7, 41-48 (2012).
  131. Echigo, R., Sugimoto, N., Yachie, A. & Ohno-Shosaku, T. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-kappaB and cell growth in U87MG human malignant glioma cells. Oncol Rep (2012).
  132. Brown, I. et al. Cannabinoids and Omega-3/6 Endocannabinoids as Cell Death and Anticancer Modulators. Prog Lipid Res (2012).
  133. Khasabova, I. A. et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 32, 7091-7101 (2012).
  134. Rajesh, M. et al. Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy. Diabetes (2012).
  135. Takeda, S. et al. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett (2012).
  136. Ramer, R. et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26, 1535-1548 (2012).
  137. Solinas, M. et al. CANNABIDIOL INHIBITS ANGIOGENESIS BY MULTIPLE MECHANISMS. Br J Pharmacol (2012).
  138. Zhornitsky, S. & Potvin, S. Cannabidiol in Humans-The Quest for Therapeutic Targets. Pharmaceuticals (Basel) 5, 529-552 (2012).
  139. Massi, P., Solinas, M., Cinquina, V. & Parolaro, D. CANNABIDIOL AS POTENTIAL ANTICANCER DRUG. Br J Clin Pharmacol (2012).
  140. Karmaus, P. W., Wagner, J. G., Harkema, J. R., Kaminski, N. E. & Kaplan, B. L. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. J Immunotoxicol (2012).
  141. Liu, X. et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor- dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 11, 1421-1431 (2012).
  142. Vidinsky, B. et al. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol (Praha) 58, 75-80 (2012).
  143. Li, K. et al. Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-
  144. Induced Acute Pancreatitis in Mice. Pancreas (2012).
  145. Rettori, E., De Laurentiis, A., Zorrilla Zubilete, M., Rettori, V. & Elverdin, J. C. Anti-Inflammatory Effect of the Endocannabinoid Anandamide in Experimental Periodontitis and Stress in the Rat. Neuroimmunomodulation 19, 293-303 (2012).
  146. Laezza, C. et al. Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer (2012).
  147. Johnson, J. R., Lossignol, D., Burnell-Nugent, M. & Fallon, M. T. An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer- Related Pain Refractory to Strong Opioid Analgesics. J Pain Symptom Manage (2012).
  148. Schicho, R. & Storr, M. A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol (2012).
  149. Kreisl, T. N. et al. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol (2012).
  150. Simpson, C. D. et al. A genome wide shRNA screen identifies alpha/beta hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance. Apoptosis (2012).
  151. Liao, Y. S., Wu, J., Wang, P. & Zhang, H. [Anandamide inhibits the growth of colorectal cancer cells through CB1 and lipid rafts.]. Zhonghua Zhong Liu Za Zhi 33, 256-259 (2011).
  152. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15, 297-308 (2011).
  153. Garami, A. et al. Thermoregulatory phenotype of the trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis. J Neurosci 31, 1721-1733 (2011).
  154. Karasu, T., Marczylo, T. H., Maccarrone, M. & Konje, J. C. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum Reprod Update (2011).
  155. Wasik, A. M., Christensson, B. & Sander, B. The role of cannabinoid receptors and the endocannabinoid system in mantle cell lymphoma and other non-Hodgkin lymphomas. Semin Cancer Biol (2011).
  156. Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene 30, 139-141 (2011).
  157. Bowles, D. W., O’Bryant, C. L., Camidge, D. R. & Jimeno, A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol (2011).
  158. Steiner, A. A. et al. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol (2011).
  159. Di Sabatino, A. et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol (2011).
  160. Horvath, B., Mukhopadhyay, P., Hasko, G. & Pacher, P. The Endocannabinoid System: Plant-Derived Cannabinoids in Diabetes and Diabetic Complications. Am J Pathol (2011).
  161. Grimaldi, C. & Capasso, A. The Endocannabinoid System in the Cancer Therapy: An Overview. Curr Med Chem (2011).
  162. Diaz-Laviada, I. The endocannabinoid system in prostate cancer. Nat Rev Urol(2011).
  163. Guindon, J. & Hohmann, A. G. The endocannabinoid system and cancer: Therapeutic Implications. Br J Pharmacol (2011).
  164. Moreno-Sanz, G. et al. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. Pharmacol Res (2011).
  165. Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid- terpenoid entourage effects. Br J Pharmacol 163, 1344-1364 (2011).
  166. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ (2011).
  167. Foroughi, M., Hendson, G., Sargent, M. A. & Steinbok, P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis inhalation. Childs Nerv Syst 27, 671-679 (2011).
  168. Zoppi, S. et al. Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36, 805-818 (2011).
  169. Ren, Y., Xu, Y. J. & Tan, Z. M. Possible involvement of the endocannabinoid system in memory modulation effect of general anesthetics. Med Hypotheses (2011).
  170. Marshall, A. D., Lagutina, I. & Grosveld, G. C. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 71, 7471-7480 (2011).
  171. Ali, A. M., Greenberg, D., Wishart, G. C. & Pharoah, P. Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England. Br J Cancer 104, 564-570 (2011).
  172. Brown, I. et al. Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids (2011).
  173. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol 650, 64-71 (2011).
  174. Nomura, D. K. et al. Monoacylglycerol Lipase Exerts Dual Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. Chem Biol 18, 846-856 (2011).
  175. Ye, L. et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett (2011).
  176. Clark, P. A., Capuzzi, K. & Fick, C. Medical marijuana: Medical necessity versus political agenda. Med Sci Monit 17, RA249-RA261 (2011).
  177. Trabert, B., Sigurdson, A. J., Sweeney, A. M., Strom, S. S. & McGlynn, K. A. Marijuana use and testicular germ cell tumors. Cancer 117, 848-853 (2011).
  178. Proto, M. C. et al. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol (2011).
  179. Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G. & Safe, S. H. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res 31, 3799-3807 (2011).
  180. Hamtiaux, L. et al. Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism. PLoS One 6, e26823 (2011).
  181. Khasabova, I. A., Chandiramani, A., Harding-Rose, C., Simone, D. A. & Seybold, V. S. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res (2011).
  182. Lou, Z. Y., Zhao, C. B. & Xiao, B. G. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J Neurosci Res (2011).
  183. Mukhopadhyay, P. et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 50, 179- 195 (2011).
  184. Ruhaak, L. R. et al. Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa. Biol Pharm Bull 34, 774-778 (2011).
  185. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163, 1479-1494 (2011).
  186. Matuszak, N. et al. Dual inhibition of MAGL and type II topoisomerase by N- phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth. Eur J Pharm Sci (2011).
  187. Purohit, V., Rapaka, R. & Shurtleff, D. Drugs of abuse, dopamine, and HIV- associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44, 102-110 (2011).
  188. Filipeanu, C. M., Guidry, J. J., Leonard, S. T. & Winsauer, P. J. Delta9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use. J Neurochem 118, 1101-1112 (2011).
  189. Brisbois, T. D. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol (2011).
  190. Argaw, A. et al. Concerted Action of CB1 Cannabinoid Receptor and Deleted in Colorectal Cancer in Axon Guidance. J Neurosci 31, 1489-1499 (2011).
  191. Ware, M. A. Clearing the smoke around medical marijuana. Clin Pharmacol Ther 90, 769-771 (2011).
  192. Brighton, P. J., Marczylo, T. H., Rana, S., Konje, J. C. & Willets, J. M. Characterising the endocannabinoid system, CB1 receptor signalling and desensitization in human myometrium. Br J Pharmacol (2011).
  193. Khasabova, I. A. et al. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 22, 607-616 (2011).
  194. Hermanson, D. J. & Marnett, L. J. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev (2011).
  195. Wilner, L. S. & Arnold, R. M. Cannabinoids in the treatment of symptoms in cancer and AIDS, 2nd edition #93. J Palliat Med 14, 509-510 (2011).
  196. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett 488, 247-251 (2011).
  197. Preet, A. et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4, 65- 75 (2011).
  198. Ruiz-Valdepenas, L. et al. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J Neuroinflammation 8, 5 (2011).
  199. Shrivastava, A., Kuzontkoski, P. M., Groopman, J. E. & Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10, 1161-1172 (2011).
  200. Kuc, C., Jenkins, A. & Van Dross, R. T. Arachidonoyl ethanolamide (AEA)- induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade. Mol Carcinog (2011).
  201. Park, J. M. et al. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. J Cell Biochem (2011).
  202. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat 94, 34-43 (2011).
  203. Perwitasari, D. A. et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33, 33-43 (2011).
  204. Wu, X. et al. Alteration of endocannabinoid system in human gliomas. J Neurochem (2011).
  205. Listed, N. A. Adverse effects of cannabis. Prescrire Int 20, 18-23 (2011).
  206. Torres, S. et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Mol Cancer Ther 10, 90-103 (2011).
  207. Wu, W. J. et al. [Membrane cholesterol mediates the endocannabinoids-anandamide effection on HepG2 cells.]. Zhonghua Gan Zang Bing Za Zhi 18, 204-208 (2010).
  208. Peat, S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs 16, 481- 485 (2010).
  209. Fowler, C. J., Hammarsten, P. & Bergh, A. Tumour Cannabinoid CB(1) Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer. PLoS One 5, e15205 (2010).
  210. Yamada, T. et al. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 76, 509.e1-509.e7 (2010). 
  211. Tazi, E. & Errihani, H. Treatment of cachexia in oncology. Indian J Palliat Care 16,129-137 (2010).
  212. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-{gamma}. J Biol Chem (2010).
  213. Lin, H. C. et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol (2010).
  214. Nallendran, V. et al. The plasma levels of the endocannabinoid, anandamide, increase with the induction of labour. BJOG (2010).
  215. Guida, M. et al. The levels of the endocannabinoid receptor CB2 and its ligand 2- arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology 151, 921-928 (2010).
  216. De Laurentiis, A. et al. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J Neuroimmunol (2010).
  217. Nunez, M., Perdomo, S., Moreta, J., Santos-Briz, A. & Gonzalez-Sarmiento, R. The

  218. G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients.Clin Transl Oncol 12, 825-828 (2010).
  219. Santha, P., Jenes, A., Somogyi, C. & Nagy, I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. Acta Physiol Hung 97, 149-158 (2010).
  220. Fowler, C. J. et al. Targeting the Endocannabinoid System for the Treatment of Cancer - A Practical View. Curr Top Med Chem (2010).
  221. Gao, M., Wang, M., Miller, K. D., Hutchins, G. D. & Zheng, Q. H. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorg Med Chem (2010).
  222. Lam, P. M., Marczylo, T. H. & Konje, J. C. Simultaneous measurement of three N- acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2010).
  223. Gallotta, D. et al. Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. Biochem Pharmacol (2010).
  224. Miranville, A., Herling, A. W., Biemer-Daub, G. & Voss, M. D. Reversal of Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages. Obesity (Silver Spring) (2010).
  225. Kawamata, T., Niiyama, Y., Yamamoto, J. & Furuse, S. Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition. J Anesth (2010).
  226. Amoako, A. A. et al. Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010).
  227. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70, 656-663 (2010).
  228. Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S. & Huestis, M. A. Plasma Cannabinoid Pharmacokinetics following Controlled Oral {Delta}9- Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. Clin Chem (2010).
  229. McAllister, S. D. et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat (2010).
  230. Fernandez-Solari, J., Prestifilippo, J. P., Ossola, C. A., Rettori, V. & Elverdin, J. C. Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. Arch Oral Biol (2010).
  231. Jesus, M. L. et al. Opposite changes in cannabinoid CB(1) and CB(2) receptor expression in human gliomas. Neurochem Int (2010).
  232. Frampton, G., Coufal, M., Li, H., Ramirez, J. & Demorrow, S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Exp Cell Res (2010).
  233. Fonseca, B. M. et al. N-Acylethanolamine Levels and Expression of Their Metabolizing Enzymes during Pregnancy. Endocrinology (2010).
  234. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61 (2010).
  235. Rask-Andersen, M., Olszewski, P. K., Levine, A. S. & Schioth, H. B. Molecular mechanisms underlying anorexia nervosa: focus on human gene association studies and systems controlling food intake. Brain Res Rev 62, 147-164 (2010).
  236. Lee, T. Y., Lee, K. C. & Chang, H. H. Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis. Apoptosis (2010).
  237. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 53, 298-306 (2010).
  238. Van Ryckeghem, F. & Van Belle, S. Management of chemotherapy-induced nausea and vomiting. Acta Clin Belg 65, 305-310 (2010).
  239. Laezza, C. et al. Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell. Endocr Relat Cancer (2010).
  240. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol (2010).
  241. Thors, L. et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One 5, e12275 (2010).
  242. Petrosino, S. & Di Marzo, V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11, 51-62 (2010).
  243. Berner, C. et al. Epigenetic Control of Estrogen Receptor Expression and Tumor Suppressor Genes Is Modulated by Bioactive Food Compounds. Ann Nutr Metab 57, 183-189 (2010).
  244. Soneji, N. D., Paule, C. C., Mlynarczyk, M. & Nagy, I. Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. Life Sci (2010).
  245. Linsalata, M. et al. Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. Anticancer Res 30, 2583-2589 (2010).
  246. Xian, X. S. et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. J Cell Biochem (2010).
  247. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double transgenic mice. Brain Res (2010).
  248. Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology (2010).
  249. Posavad, C. M. et al. Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons. J Immunol (2010).
  250. Mingorance, C., de Sotomayor, M. A., Marhuenda, E. & Herrera, M. D. Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats. J Cardiovasc Pharmacol 56, 560-569 (2010).
  251. Ward, H., Luben, R. N., Wareham, N. J. & Khaw, K. T. CHD risk in relation to alcohol intake from categorical and open-ended dietary instruments. Public Health Nutr 1-8 (2010).
  252. Liu, W. M., Fowler, D. W. & Dalgleish, A. G. Cannabis-Derived Substances in Cancer Therapy - an Emerging Anti-Inflammatory Role for the Cannabinoids. Curr Clin Pharmacol (2010).
  253. Carter, G. T., Abood, M. E., Aggarwal, S. K. & Weiss, M. D. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 27, 347-356 (2010).
  254. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9, 196 (2010).
  255. Whyte, D. A. et al. Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells. Pharmacology 85, 328-335 (2010).
  256. Reiss, C. S. Cannabinoids and Viral Infections. Pharmaceuticals (Basel) 3, 1873- 1886 (2010).
  257. Preet, A. et al. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Prev Res (Phila) (2010).
  258. Brown, I. et al. Cannabinoid receptor dependent and independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor positive and negative prostate cancer cell lines. Carcinogenesis (2010).
  259. Larrinaga, G. et al. Cannabinoid CB1 Receptor Is Down-regulated in Clear Cell Renal Cell Carcinoma. J Histochem Cytochem (2010).
  260. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2) Receptors in Health and Disease. Curr Med Chem (2010).
  261. Marcu, J. P. et al. Cannabidiol enhances the inhibitory effects of Delta9- tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9, 180-189 (2010).
  262. Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S. & Stinchcomb, A. L. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm 36, 1088-1097 (2010).
  263. LIU, D. Z., HU, C. M., HUANG, C. H., WEY, S. P. & JAN, T. R. Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity. Acta Pharmacol Sin 31, 1611-1617 (2010).
  264. Rajesh, M. et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56, 2115-2125 (2010).
  265. Cui, J. H. et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett (2010).
  266. Jordan, K. et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer (2010).
  267. Phillips, R. S. et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 9, CD007786 (2010).
  268. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative Effect of a Putative Endocannabinoid; 2-Arachidonylglyceryl Ether in Prostate Carcinoma Cells. Prostaglandins Other Lipid Mediat (2010).
  269. Marczylo, T. H., Lam, P. M., Amoako, A. A. & Konje, J. C. Anandamide levels in human female reproductive tissues: solid-phase extraction and measurement by ultraperformance liquid chromatography tandem mass spectrometry. Anal Biochem 400, 155-162 (2010).
  270. Yang, Q., Liu, H. Y., Zhang, Y. W., Wu, W. J. & Tang, W. X. Anandamide induces cell death through lipid rafts in hepatic stellate cells. J Gastroenterol Hepatol (2010).
  271. Koo, J. S. & Jung, W. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1alpha regulation in human breast cancer. Pathobiology 77, 289-300 (2010).
  272. Park, J. Y. et al. Alcohol intake and risk of colorectal cancer: Results from the UK Dietary Cohort Consortium. Br J Cancer (2010).
  273. Labar, G., Wouters, J. & Lambert, D. M. A Review on the Monoacylglycerol Lipase: At the Interface between Fat and Endocannabinoid Signalling. Curr Med Chem (2010).
  274. Hsu, E. S. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther 17, 476-486 (2010).
  275. Miro, A. M. et al. 17beta-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol (2010).
  276. Pisanti, S. et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 23, 117-131 (2009).
  277. El-Talatini, M. R., Taylor, A. H. & Konje, J. C. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril (2009).
  278. Guindon, J. & Hohmann, A. G. The Endocannabinoid System and Pain. CNS Neurol Disord Drug Targets (2009).
  279. Leelawat, S., Leelawat, K., Narong, S. & Matangkasombut, O. The Dual Effects of Delta(9)-Tetrahydrocannabinol on Cholangiocarcinoma Cells: Anti-Invasion Activity at Low Concentration and Apoptosis Induction at High Concentration. Cancer Invest (2009).
  280. Luca, T. et al. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitro. Eur J Pharmacol 616, 16-21 (2009).
  281. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. The cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol (2009).
  282. Stubbs, M. & Griffiths, J. R. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul (2009).
  283. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther (2009).
  284. Borrelli, F. & Izzo, A. A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23, 33-49 (2009).
  285. Santoro, A. et al. Rimonabant inhibits human colon cancer cell growth and reducesthe formation of precancerous lesions in the mouse colon. Int J Cancer (2009).
  286. Furuse, S. et al. Reduction of Bone Cancer Pain by Activation of Spinal Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the Spinal Cord in a Murine Model of Bone Cancer Pain. Anesthesiology (2009).
  287. Wang, Q. et al. Pretreatment With Electroacupuncture Induces Rapid Tolerance to Focal Cerebral Ischemia Through Regulation of Endocannabinoid System. Stroke (2009).
  288. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79, 333-337 (2009).
  289. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A. & Flygare, J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res 7, 1086-1098 (2009).
  290. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non- psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009).
  291. Surtees, P. G., Wainwright, N. W., Luben, R. N., Khaw, K. T. & Bingham, S. A. No evidence that social stress is associated with breast cancer incidence. Breast Cancer Res Treat (2009).
  292. Surtees, P. G. et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. J Psychiatr Res (2009).
  293. Brizzi, A. et al. New Resorcinol-Anandamide “Hybrids” as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. J Med Chem (2009).
  294. Wegener, N. & Koch, M. Neurobiology and Systems Physiology of the Endocannabinoid System. Pharmacopsychiatry 42, S79-S86 (2009).
  295. Keeley, P. W. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009, (2009).
  296. Galal, A. M. et al. Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications. Recent Pat CNS Drug Discov 4, 112-136 (2009).
  297. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. J Pain Symptom Manage (2009).
  298. Takeda, S., Yamamoto, I. & Watanabe, K. Modulation of Delta(9)- tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology 259, 25-32 (2009).
  299. Van Dross, R. T. Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog (2009).
  300. Berthiller, J. et al. Marijuana Smoking and the Risk of Head and Neck Cancer: Pooled Analysis in the INHANCE Consortium. Cancer Epidemiol Biomarkers Prev 18, 1544-1551 (2009).
  301. El-Talatini, M. R. et al. Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 4, e4579 (2009).
  302. Yin, H. et al. Lipid G-protein-coupled Receptor Ligand Identification Using beta - arrestin Pathhunter Assay. J Biol Chem (2009).
  303. Yin, H. et al. Lipid G protein-coupled receptor ligand identification using beta- arrestin PathHunter assay. J Biol Chem 284, 12328-12338 (2009).
  304. De Filippis, D. et al. LEVELS OF ENDOCANNABINOIDs AND PALMITOYLETHANOLAMIDE AND THEIR PHARMACOLOGICAL MANIPULATION IN CHRONIC GRANULOMATOUS INFLAMMATION IN RATs. Pharmacol Res (2009).
  305. Tournier, N. et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 1-11 (2009).
  306. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2). Br J Cancer (2009).
  307. El-Talatini, M. R., Taylor, A. H. & Konje, J. C. Fluctuation in anandamide levels from ovulation to early pregnancy in in-vitro fertilization-embryo transfer women, and its hormonal regulation. Hum Reprod (2009).
  308. Moayyeri, A. et al. Estimation of absolute fracture risk among middle-aged and older men and women: the EPIC-Norfolk population cohort study. Eur J Epidemiol (2009).
  309. Pisanti, S. & Bifulco, M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 60, 107-116 (2009).
  310. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156, 397-411 (2009).
  311. Gao, F. F. et al. Egr-1, a central and unifying role in cardioprotection from ischemia-reperfusion injury? Cell Physiol Biochem 24, 519-526 (2009).
  312. Cotter, J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. Oncol Nurs Forum 36, 345-352 (2009).
  313. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 3, 7-13 (2009).
  314. Udler, M. S. et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer (2009).
  315. Brighton, P. J. et al. Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells. Mol Endocrinol (2009).
  316. Bifulco, M., Santoro, A., Laezza, C. & Malfitano, A. M. Chapter 7 Cannabinoid Receptor CB1 Antagonists State of the Art and Challenges. Vitam Horm 81, 159- 189 (2009).
  317. Alpini, G. & Demorrow, S. Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer. Vitam Horm 81C, 469-485 (2009).
  318. Villanueva, A. et al. Central Cannabinoid-1 Receptor Antagonist Administration Prevents Endotoxic Hypotension Affecting Norepinephrine Release in the Preoptic Anterior Hypothalamic Area. Shock (2009).
  319. Han, K. H. et al. CB1 and CB2 Cannabinoid Receptors Differentially Regulate the Production of Reactive Oxygen Species by Macrophages. Cardiovasc Res (2009).
  320. Froger, N. et al. Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. J Neurochem 111, 1383-1397 (2009).
  321. Alexander, A., Smith, P. F. & Rosengren, R. J. Cannabinoids in the treatment of cancer. Cancer Lett 285, 6-12 (2009).
  322. Izzo, A. A. & Camilleri, M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res (2009).
  323. Oesch, S. & Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? J Pharm Pharmacol 61, 839-853 (2009).
  324. Zhao, P., Leonoudakis, D., Abood, M. E. & Beattie, E. Cannabinoid Receptor Activation Reduces TNFalpha-Induced Surface Localization of AMPAR-Type Glutamate Receptors and Excitotoxicity. Neuropharmacology (2009).
  325. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther (2009).
  326. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009).
  327. Ramer, R., Merkord, J., Rohde, H. & Hinz, B. Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1. Biochem Pharmacol (2009).
  328. Napimoga, M. H. et al. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 9, 216-222 (2009).
  329. Magen, I. et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 51, 528-534 (2009).
  330. Mantovani, G. & Madeddu, C. Cancer cachexia: medical management. Support Care Cancer (2009).
  331. Gallant, M., Odei-Addo, F., Frost, C. L. & Levendal, R. A. Biological effects of THC and a lipophilic cannabis extract on normal and insulin resistant 3T3-L1 adipocytes. Phytomedicine (2009).
  332. Daling, J. R. et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer (2009).
  333. Dunning, A. M. et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009).
  334. Freimuth, N., Ramer, R. & Hinz, B. Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther (2009).
  335. Murakami, T. et al. Antimicrobial cathelicidin polypeptide CAP11 suppresses the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice. Int Immunol (2009).
  336. Navari, R. M. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 10, 629-644 (2009).
  337. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids, their congeners and COX-2 metabolites. J Chromatogr B Analyt Technol Biomed Life Sci (2009).
  338. Madeddu, C. & Mantovani, G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care (2009).
  339. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells tocannabinoid-induced apoptosis. Glia (2009).
  340. Liang, C. et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila Pa) (2009).
  341. Ernst, G. & Kongsgaard, U. E. [Use of cannabinoids in palliative medicine.]. Tidsskr Nor Laegeforen 128, 822-825 (2008).
  342. Lam, P. M. et al. Ultra Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Measurement of Anandamide in Human Plasma. Anal Biochem (2008).
  343. Bari, M. et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology 54, 45-50 (2008).
  344. DUBOIS. Turned-off Cannabinoid Receptor Turns on Colorectal Tumor Growth. Newswise (2008).
  345. Machado Rocha, F. C., Stefano, S. C., DE Cassia Haiek, R., Rosa Oliveira, L. M. & DA Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) (2008).
  346. Rudolph, M. I. et al. The Influence of Mast Cell Mediators on Migration of SW756 Cervical Carcinoma Cells. J Pharmacol Sci 106, 208-218 (2008).
  347. Bilsland, L. G. & Greensmith, L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 14, 2306-2316 (2008).
  348. Lissoni, P. et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. Anticancer Res 28, 3743-3748 (2008).
  349. Demorrow, S. et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol 294, G506-G519 (2008).
  350. Coffman, K. L. The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. Curr Opin Organ Transplant 13, 189-195 (2008).
  351. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68, 3992-3998 (2008).
  352. Potenzieri, C., Harding-Rose, C. & Simone, D. A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res (2008).
  353. Laezza, C., Pisanti, S., Malfitano, A. M. & Bifulco, M. The anandamide analogue, Met-F-AEA, controls human breast cancer cell migration via the RhoA/Rho kinase signaling pathway. Endocr Relat Cancer (2008).
  354. Dahlstrom, K. R. et al. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 30, 75-84 (2008).
  355. Kerr, J. R. et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol 61, 730-739 (2008).
  356. Rahn, E. J. et al. Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. J Pharmacol Exp Ther (2008).
  357. Santoro, A. et al. Reply to the letter to the editor “Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer”. Int J Cancer (2008).
  358. Eichele, K., Ramer, R. & Hinz, B. R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway. Pharm Res (2008).
  359. Surtees, P. G. et al. Psychological distress, major depressive disorder, and risk of stroke. Neurology 70, 788-794 (2008).
  360. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008).
  361. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325, 1007-1015 (2008).
  362. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin type-8 (TRPM-8). J Pharmacol Exp Ther (2008).
  363. Alfranca, A. et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 112, 1120-1128 (2008).
  364. El-Remessy, A. B. et al. Neuroprotective effects of cannabidiol in endotoxin- induced uveitis: critical role of p38 MAPK activation. Mol Vis 14, 2190-2203 (2008).
  365. Liou, G. I. et al. Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A2A Adenosine Receptor. Invest Ophthalmol Vis Sci (2008).
  366. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68, 6468-6476 (2008).
  367. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Delta(9)- tetrahydrocannabinol on human breast cancer cells. Oncogene (2008).
  368. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100, 59-69 (2008).
  369. Czifra, G. et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol (2008).
  370. Chen, A. L. et al. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs 40, 263-272 (2008).
  371. Widmer, M., Hanemann, O. & Zajicek, J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J Neurosci Res (2008).
  372. Habayeb, O. M., Taylor, A. H., Bell, S. C., Taylor, D. J. & Konje, J. C. Expression of the Endocannabinoid System in Human First Trimester Placenta and its Role in Trophoblast Proliferation. Endocrinology (2008).
  373. Gustafsson, K. et al. Expression of Cannabinoid Receptors Type 1 and Type 2 in Non-hodkin Lymphoma: Growth Inhibition By Receptor Activation. Int J Cancer (2008).
  374. Wang, J. et al. Expression and secretion of N-acylethanolamine-hydrolyzing acid amidase in human prostate cancer cells. J Biochem (2008).
  375. Massi, P., Valenti, M., Bolognini, D. & Parolaro, D. Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des 14, 2289-2298 (2008).
  376. Endsley, M. P. et al. Expression and Function of Fatty Acid Amide Hydrolase in Prostate Cancer. Int J Cancer (2008).
  377. Notarnicola, M. et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 43, 66-72 (2008).
  378. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog Retin Eye Res (2008).
  379. Bifulco, M., Malfitano, A. M., Pisanti, S. & Laezza, C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15, 391-408 (2008).
  380. Blazquez, C. et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 54, 235-243 (2008).
  381. Fowler, C. J. & Ghafouri, N. Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? Pharmacol Res (2008).
  382. von Bueren, A. O., Schlumpf, M. & Lichtensteiger, W. Delta(9)- tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res 28, 85-89 (2008).
  383. Galanti, G. et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 47, 1062-1070 (2008).
  384. Deutsch, S. I. et al. Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol. CNS Spectr 13, 393-403 (2008).
  385. Warr, D. G. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol 15, S4-S9 (2008).
  386. Brambilla, C. & Colonna, M. Cannabis: the next villain on the lung cancer battlefield? Eur Respir J 31, 227-228 (2008).
  387. Aldington, S. et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 31, 280-286 (2008).
  388. Aldington, S. et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 138, 374-380 (2008).
  389. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels. Inhal Toxicol 1 (2008).
  390. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 68, 1945-1952 (2008).
  391. Russo, E. B. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4, 245-259 (2008).
  392. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 68, 339-342 (2008).
  393. Iribarne, M. et al. Cannabinoid Receptors in Conjunctival Epithelium: Identification and Functional Properties. Invest Ophthalmol Vis Sci (2008).
  394. Jones, J. D., Carney, S. T., Vrana, K. E., Norford, D. C. & Howlett, A. C. Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. Neuropharmacology 54, 23-30 (2008).
  395. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol (2008).
  396. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB(2) receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008).
  397. Cianchi, F. et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor {alpha}-Mediated Ceramide De novo Synthesis in Colon Cancer Cells. Clin Cancer Res 14, 7691-7700 (2008).
  398. Shi, Y. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 15, 101-107 (2008).
  399. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30, 271-280 (2008).
  400. Weiss, L. et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54, 244-249 (2008).
  401. Roderick, H. L. & Cook, S. J. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 8, 361-375 (2008).
  402. Giuliano, M. et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARgamma. Biochimie (2008).
  403. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42 Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and Cannabinoids. Neurotoxicol Teratol (2008).
  404. Stebulis, J. A., Johnson, D. R., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci 83, 666-670 (2008).
  405. Sugamura, K. et al. Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Circulation (2008).
  406. Marczylo, T. H., Lam, P. M., Nallendran, V., Taylor, A. H. & Konje, J. C. A solid- phase method for the extraction and measurement of anandamide from multiple human biomatrices. Anal Biochem (2008).
  407. Ware1, M. A., Daeninck, P. & Maida, V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 4, 99-107 (2008).
  408. Chung, S. C. et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008).
  409. Khasabova, I. A. et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28, 11141-11152 (2008).
  410. Diaz, P. et al. 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. J Med Chem (2008).
  411. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104, 1091-1100 (2008).
  412. Gkoumassi, E. et al. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br J Pharmacol (2007).
  413. Taylor, A. H., Ang, C., Bell, S. C. & Konje, J. C. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum Reprod Update (2007).
  414. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14, 917-936 (2007).
  415. Holland, M. L., Lau, D. T., Allen, J. D. & Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol (2007).
  416. Flygare, J. & Sander, B. The endocannabinoid system in cancer-Potential therapeutic target? Semin Cancer Biol (2007).
  417. Greenhough, A., Patsos, H. A., Williams, A. C. & Paraskeva, C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer (2007).
  418. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 19, 704-708 (2007).
  419. Johnson, D. R., Stebulis, J. A., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 100, 184-190 (2007).
  420. Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S. & Santoro, A. Rimonabant: Just an Anti-obesity Drug? Current Evidence on Its Pleiotropic Effects. Mol Pharmacol (2007).
  421. Gary-Bobo, M. et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (2007).
  422. Darmani, N. A., Janoyan, J. J., Crim, J. & Ramirez, J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol S (2007).
  423. Demorrow, S. et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of fas and fas ligand to lipid rafts. J Biol Chem S (2007).
  424. Engels, F. K. et al. Medicinal cannabis in oncology. Eur J Cancer 43, 2638-2644 (2007).
  425. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm 64, 1037-1044 (2007).
  426. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. AIDS Care S 19, 295-301 (2007).
  427. De Filippis, D. et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. JMol Med (2007).
  428. Kingsley, P. J. & Marnett, L. J. LC-MS-MS Analysis of Neutral Eicosanoids. Methods Enzymol 433, 91-112 (2007).
  429. Varvel, S. A., Martin, B. R. & Lichtman, A. H. Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. Psychopharmacology (Berl) (2007).
  430. Thors, L., Alajakku, K. & Fowler, C. J. The ‘specific’ tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol (2007).
  431. Tham, C. S., Whitaker, J., Luo, L. & Webb, M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 581, 2899-2904 (2007).
  432. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (2007).
  433. Kempf, K. et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res 39, 596-600 (2007).
  434. Vila, A., Rosengarth, A., Piomelli, D., Cravatt, B. & Marnett, L. J. Hydrolysis of Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes, Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase. Biochemistry (2007).
  435. Peters, M. & Kogan, N. M. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin Investig Drugs 16, 1405-1413 (2007).
  436. Bifulco, M., Laezza, C., Gazzerro, P. & Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review). Oncol Rep 17, 813-816 (2007).
  437. Mukhopadhyay, S. & Tulis, D. A. Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem 5, 311-318 (2007).
  438. Sunil K. Aggarwal, M. S. I. I. I., PhC, BS, BA; Muraco Kyashna-Tocha, PhD; Gregory T. Carter, MD, MS. Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. (2007).
  439. Endsley, M. P. et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer (2007).
  440. Schramm-Sapyta, N. L. et al. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl) S (2007).
  441. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene (2007).
  442. Takeda, S. et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology (2007).
  443. Batkai, S. et al. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 293, H909-H918 (2007).
  444. Jordan, K., Schmoll, H. J. & Aapro, M. S. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol S (2007).
  445. Udler, M. et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25, 3015-3023 (2007).
  446. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. Chem Biodivers 4, 1729-1743 (2007).
  447. Aguado, T. et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem S (2007).
  448. Slatkin, N. E. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5, 1-9 (2007).
  449. Michalski, C. W. et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. Int J Cancer (2007).
  450. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. Dialogues Clin Neurosci 9, 413-430 (2007).
  451. D’Souza, D. C. Cannabinoids and psychosis. Int Rev Neurobiol S 78, 289-326 (2007).
  452. Velasco, G. et al. Cannabinoids and gliomas. Mol Neurobiol 36, 60-67 (2007).
  453. Athanasiou, A. et al. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364, 131-137 (2007).
  454. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid Modulation of Kaposi’s Sarcoma Associated Herpesvirus Infection and Transformation. Cancer Res 67, 7230-7237 (2007).
  455. McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A. & Desprez, P. Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6, 2921-2927 (2007).
  456. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. Cas Lek Cesk 145, 453-7; discussion 458 (2006).
  457. Vignot, S. et al. [Cannabis and cancer]. Bull Cancer 93, 163-170 (2006).
  458. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6, 656-665 (2006).
  459. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18, 1584-1594 (2006).
  460. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: current status. Methods Find Exp Clin Pharmacol 28, 177-183 (2006).
  461. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).
  462. Massi, P. et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci (2006).
  463. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58, 389-462 (2006).
  464. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer (2006).
  465. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 71, 1146-1154 (2006).
  466. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramide- dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res (2006).
  467. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid Rafts Mediated Mechanism. Mol Pharmacol (2006).
  468. Mehra, R., Moore, B. A., Crothers, K., Tetrault, J. & Fiellin, D. A. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 166, 1359-1367 (2006).
  469. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530, 54-58 (2006).
  470. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm Res 23, 90-94 (2006).
  471. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori, V. Participation of the Endocannabinoid System in the Effect of TNF-{alpha} on Hypothalamic Release of Gonadotropin-Releasing Hormone. Ann N Y Acad Sci S 1088, 238-250 (2006).
  472. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. J Org Chem 71, 7800-7804 (2006).
  473. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171, 31-38 (2006).
  474. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6, 257-268 (2006).
  475. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 49, 1113-1117 (2006).
  476. El-Remessy, A. B. et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168, 235-244 (2006).
  477. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55, 946-953 (2006).
  478. Hashibe, M. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 15, 1829-1834 (2006).
  479. Thors, L. & Fowler, C. J. Is there a temperature-dependent uptake of anandamide into cells? Br J Pharmacol 149, 73-81 (2006).
  480. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J Leukoc Biol 79, 202-213 (2006).
  481. Alsasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. Cell Mol Neurobiol (2006).
  482. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor

  483. CB2. Immunogenetics 58, 714-725 (2006). 478. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest 116, 2122-2131 (2006).
  484. Berlach, D. M., Shir, Y. & Ware, M. A. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 7, 25-29 (2006).
  485. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. Interjournal Complex Systems 1669 (2006).
  486. Stein, L. A. et al. Effects of motivational interviewing for incarcerated adolescents on driving under the influence after release. Am J Addict 15 Suppl 1, 50-57 (2006).
  487. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. & Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res S (2006).
  488. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. Anal Biochem SO - Anal Biochem. 2006 Dec 20;d (2006).
  489. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. Mol Cancer Res 4, 549-562 (2006).
  490. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Delta}9- Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. Cancer Res 66, 6615-6621 (2006).
  491. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283, 75-83 (2006).
  492. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24, 3394- 3400 (2006).
  493. Perez, J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42, 495-503 (2006).
  494. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. Pediatr Res (2006).
  495. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 12, 3135-3146 (2006).
  496. Carracedo, A. et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66, 6748-6755 (2006).
  497. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105, 1-25 (2006).
  498. Huskey, A. Cannabinoids in cancer pain management. J Pain Palliat Care Pharmacother 20, 43-46 (2006).
  499. Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148, 123-135 (2006).
  500. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol (2006).
  501. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R. Cannabinoid receptors in human astroglial tumors. J Neurochem 98, 886-893 (2006).
  502. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J (2006).
  503. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem (2006).
  504. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6, 677-684 (2006).
  505. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett 580, 1733-1739 (2006).
  506. McKallip, R. J. et al. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 70, 897-908 (2006)
  507. Weiss, L. et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39, 143-151 (2006).
  508. Chacko, J. A., Heiner, J. G., Siu, W., Macy, M. & Terris, M. K. Association between marijuana use and transitional cell carcinoma. Urology 67, 100-104 (2006).
  509. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. J Cell Physiol S (2006).
  510. Ligresti, A. et al. Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006).
  511. Laezza, C., Simona, P., Crescenzi, E. & Bifulco, M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 580, 6076-6082 (2006).
  512. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312, 363-373 (2006).
  513. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND - INDEPENDENT IMMUNOMODULATORY EFFECTS. J Biol Chem 281, 14192- 14206 (2006).
  514. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99, 677-688 (2006).
  515. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor- evoked hyperalgesia. Eur J Pharmacol S (2006).
  516. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66, 234-246 (2006).
  517. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer (2006).
  518. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Mol Pharmacol (2006).
  519. Patsos, H. A. et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54, 1741-1750 (2005).
  520. Walsh, D., Kirkova, J. & Davis, M. P. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. J Pain Symptom Manage 30, 493-495 (2005).
  521. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29, 915-922 (2005).
  522. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219 (2005).
  523. Tashkin, D. P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 63, 93-100 (2005).
  524. .Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913 (2005).
  525. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579, 6343-6349 (2005).
  526. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N- arachidonoyldopamine. J Immunol 175, 3990-3999 (2005).
  527. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206, 471-478 (2005).
  528. 523. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6, 93-102 (2005).
  529. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280, 12212-12220 (2005).
  530. Sun, Y. X. et al. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736, 211-220 (2005).
  531. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem (Tokyo) 137, 217-223 (2005).
  532. Fride, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230, 225-234 (2005).
  533. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs 10, 151-171 (2005).
  534. Guzman, M. Effects on cell viability. Handb Exp Pharmacol 627-642 (2005).
  535. Chung, K. F. Drugs to suppress cough. Expert Opin Investig Drugs 14, 19-27 (2005).
  536. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor
  537. immune response. J Immunol 174, 3281-3289 (2005).
  538. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 81, 275- 283 (2005).
  539. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105, 1214-1221 (2005).
  540. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct J 2, 21 (2005).
  541. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74, 31-40 (2005).
  542. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down- regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17, 25-37 (2005).
  543. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. Handb Exp Pharmacol 573-598 (2005).
  544. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33, 712-714 (2005).
  545. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6, 35-42 (2005).
  546. Kogan, N. M. Cannabinoids and cancer. Mini Rev Med Chem 5, 941-952 (2005).
  547. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5, 400-411 (2005).
  548. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579, 6885-6889 (2005).
  549. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144, 1032-1036 (2005).
  550. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. J BUON 10, 181-188 (2005).
  551. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res 28, 1365-1375 (2005).
  552. Roila, F. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 13, 129-131 (2005).
  553. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 7, E143-E148 (2005).
  554. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19, 1338-1340 (2005).
  555. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332, 1028-1033 (2005).
  556. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special emphasis on aged patients]. Nippon Ronen Igakkai Zasshi 41, 460-467 (2004).
  557. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis and endocannabinoid system]. Med Clin (Barc) 122, 390-398 (2004).
  558. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. Gastroenterol Clin Biol 28, 97 (2004).
  559. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. Rev Neurol (Paris) 160, 639-649 (2004).
  560. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. Schmerz (2004).
  561. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz 18, 203-210 (2004).
  562. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord 3, 507-514 (2004).
  563. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120, 138-144 (2004).
  564. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 44, 461-467 (2004).
  565. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4, 572-579 (2004).
  566. Juttler, E. et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor- kappa B (NF-kappa B). Neuropharmacology 47, 580-592 (2004).
  567. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47, 3800-3806 (2004).
  568. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol 492, 1-11 (2004).
  569. Karlsson, M., Pahlsson, C. & Fowler, C. J. Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur J Pharm Sci 22, 181-189 (2004).
  570. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamide- induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun 324, 621-626 (2004).
  571. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309, 745-757 (2004).
  572. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262 (2004).
  573. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis: rational guidelines for dosing. IDrugs 7, 464-470 (2004).
  574. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am 15, 943-54, ix (2004).
  575. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2, 305-14; discussion 314 (2004).
  576. Holt, S. et al. Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci 76, 461-472 (2004).
  577. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47, 315-323 (2004).
  578. Gertsch, J., Schoop, R., Kuenzle, U. & Suter, A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett 577, 563-569 (2004).
  579. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P. G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med 2, 34 (2004).
  580. Beale, R. C. et al. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 337, 585-596 (2004).
  581. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 380, 435-440 (2004).
  582. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64, 5617-5623 (2004).
  583. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64, 1943-1950 (2004).
  584. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. Schmerz 18, 197-202 (2004).
  585. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 147, 127-130 (2004).
  586. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol 63, 956-963 (2004).
  587. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93, 182-188 (2004).
  588. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308, 838-845 (2004).
  589. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53, 723-728 (2004).
  590. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863 (2004).
  591. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18, 1606-1608 (2004).
  592. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti Prog Med 94, 194-198 (2003).
  593. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. Schmerz 17, 274-279 (2003).
  594. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202 (2003).
  595. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12, 39-44 (2003).
  596. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor- dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278, 33896-33903 (2003).
  597. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6- hydroxydopamine-lesioned rats. Pharmacol Toxicol 93, 66-70 (2003).
  598. Klein, T. W. et al. The cannabinoid system and immune modulation. J Leukoc Biol 74, 486-496 (2003).
  599. Trembovler, V., Abu-Raya, S. & Shohami, E. Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells. Neurosci Lett 353, 115-118 (2003).
  600. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65, 649-655 (2003).
  601. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140, 115-122 (2003).
  602. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139, 775-786 (2003).
  603. Wrobleski, S. T. et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46, 2110-2116 (2003).
  604. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687 (2003).
  605. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9, 1607-1633 (2003).
  606. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42, 327-360 (2003).
  607. New toke on treating skin cancer. Lab Anim (NY) 32, 12 (2003).
  608. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. N- Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem 11, 817-825 (2003).
  609. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res 980, 197-205 (2003).
  610. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 17, 2157-2159 (2003).
  611. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17, 1771-1773 (2003).
  612. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17, 529-531 (2003).
  613. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111, 43-50 (2003).
  614. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458, 207-215 (2003).
  615. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1- arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol 66, 757-767 (2003).
  616. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. Adv Exp Med Biol 525, 145- 152 (2003).
  617. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. Expert Opin Pharmacother 4, 2367-2371 (2003).
  618. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells. Leuk Lymphoma 44, 1767-1773 (2003).
  619. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100, 4269-4274 (2003).
  620. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137-143 (2003).
  621. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555, 561-566 (2003).
  622. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166, 156-162 (2003).
  623. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170, 4953-4962 (2003).
  624. Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. Drugs R D 4, 185-187 (2003).
  625. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46, 2352-2360 (2003).
  626. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of Thc on Human Lung Epithelial Cells. Toxicol Appl Pharmacol (2008).
  627. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64, 1189-1198 (2003).
  628. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs R D 4, 306-309 (2003).
  629. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102, 211-216 (2003).
  630. Guzman, M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, 745-755 (2003).
  631. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104, 12-18 (2003).
  632. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary? Support Care Cancer 11, 133-134 (2003).
  633. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161-168 (2003).
  634. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced activation of ERK and AKT in mast cells may be mediated by intracellular NO production. J Immunol 171, 2767 (2003).
  635. Toth, A., Kedei, N., Wang, Y. & Blumberg, P. M. Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci 73, 487-498 (2003).
  636. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal Biochem 314, 8-15 (2003).
  637. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 42, 9041-9049 (2003).
  638. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol 77, 201-207 (2003).
  639. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15, 851-859 (2003).
  640. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278, 48973-48980 (2003).
  641. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 64, 1334-1341 (2003).
  642. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103, 175-186 (2003).
  643. Ockenga, J., Pirlich, M., Gastell, S. & Lochs, H. [Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. Z Gastroenterol 40, 929-936 (2002).
  644. Zurcher, G. [Anorectic syndrome]. Z Gastroenterol 40 Suppl 1, S71-SS5 (2002).
  645. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J Biol Chem 277, 50348-50354 (2002).
  646. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132, 1012-1017 (2002).
  647. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101, 93-102 (2002).
  648. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8, 547-550 (2002).
  649. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).
  650. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett 133, 171-179 (2002).
  651. Tashkin, D. P., Baldwin, G. C., Sarafian, T., Dubinett, S. & Roth, M. D. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42, 71S-81S (2002).
  652. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2- arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45, 3709-3720 (2002).
  653. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66, 211-220 (2002).
  654. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-44885 (2002).
  655. Kozak, K. R. et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-44885 (2002).
  656. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62, 1385-1392 (2002).
  657. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck cancer. J Clin Pharmacol 42, 103S-107S (2002).
  658. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62, 4398-4405 (2002).
  659. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66, 319-332 (2002).
  660. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66, 257-267 (2002).
  661. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16, 297-302 (2002).
  662. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. Int Immunopharmacol 2, 537-543(2002).
  663. Jatoi, A. et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20, 567-573 (2002).
  664. Jatoi, A. et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 10, 71-75 (2002).
  665. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo- synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363, 183-188 (2002).
  666. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. FEBS Lett 525, 164- 168 (2002).
  667. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs 3, 437-440 (2002).
  668. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277, 36527- 36533 (2002).
  669. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3, 859-864 (2002).
  670. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66, 101-121 (2002).
  671. 665. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an update. Adv Exp Med Biol 507, 381-386 (2002).
  672. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52, 72-91 (2002).
  673. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J 366, 137-144 (2002).
  674. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport 13, 593-596 (2002).
  675. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268, 1982-1989 (2001).
  676. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6, 67-73 (2001).
  677. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61, 955-977 (2001).
  678. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40, 861-866 (2001).
  679. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in
  680. C6 rat glioma cells. J Neurochem 78, 835-841 (2001).
  681. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59, 1369-1375 (2001).
  682. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 286, 1144-1152 (2001).
  683. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358, 249-255 (2001).
  684. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86, 2687-2696 (2001).
  685. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur J Pharmacol 425, 73-83 (2001).
  686. Kalant, H. Medicinal use of cannabis: history and current status. Pain Res Manag 6, 80-91 (2001).
  687. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)- tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol 174, 264-272 (2001).
  688. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299, 951-959 (2001).
  689. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61, 5784-5789 (2001).
  690. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24, 339-344 (2001).
  691. Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76, 594-601 (2001).
  692. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133, 1263-1275 (2001).
  693. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9- tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25, 565-571 (2001).
  694. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)- Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268, 531-535 (2001).
  695. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent

  696. emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR

  697. 141716A. Neuropsychopharmacology 24, 198-203 (2001).

  698. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. J Mol Med 78, 613-625 (2001).
  699. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene- dependent tumor growth. FASEB J 15, 2745-2747 (2001).
  700. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132, 1743-1754 (2001).
  701. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J Neurosci Res 65, 346-353 (2001).
  702. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. Pain Res Manag 6, 74-79 (2001).
  703. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).
  704. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic non- psychoactive cannabinoid. Biochem Pharmacol 62, 755-763 (2001).
  705. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134, 1151-1154 (2001).
  706. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 276, 30072-30077 (2001).
  707. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 7, 43-61 (2001).
  708. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and cannabinoids]. An R Acad Nac Med (Madr) 117, 595-605; discussion 616 (2000).
  709. Carriot, F. & Sasco, A. J. [Cannabis and cancer]. Rev Epidemiol Sante Publique 48, 473-483 (2000).
  710. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.]. Bull Cancer 87, 299-300 (2000).
  711. Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97, 9561-9566 (2000).
  712. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347, 369-373 (2000).
  713. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225, 1-8 (2000).
  714. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharm Res 23, 121-127 (2000).
  715. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J Pharmacol Exp Ther 293, 289-295 (2000).
  716. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126 (2000).
  717. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serum-

  718. dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability.

  719. Biochem Pharmacol 60, 1807-1813 (2000).

  720. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated T- cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292, 597-605 (2000).
  721. Kosior, D. A., Filipiak, K. J., Stolarz, P. & Opolski, G. Paroxysmal atrial fibrillation in a young female patient following marijuana intoxication--a case report of possible association. Med Sci Monit 6, 386-389 (2000).
  722. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G. & Di Marzo, V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483, 52-56 (2000).
  723. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res 20, 861-867 (2000).
  724. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug development. Curr Pharm Des 6, 1361-1380 (2000).
  725. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 108, 191-209 (2000).
  726. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti- inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293, 136- 150 (2000).
  727. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem 267, 2991-2997 (2000).
  728. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165, 373-380 (2000).
  729. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. Forensic Sci Int 113, 353-357 (2000).
  730. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39, 1331-1336 (2000).
  731. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPS- inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (2000).
  732. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology 141, 1675-1685 (2000).
  733. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 61, 43-61 (2000).
  734. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6, 313-319 (2000).
  735. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for

  736. a protective role of cannabinoid receptors. J Biol Chem 275, 31938-31945 (2000).

  737. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2- arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun 278, 576-583 (2000).
  738. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406, R5-R7 (2000).
  739. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9- tetrahydrocannabinol and its metabolites on the immune system]. Acta Clin Belg Suppl 1, 39-43 (1999).
  740. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262, 275-284 (1999).
  741. listed], [. N. A. Studies of high-dose chemotherapy with stem cell support for breast cancer. Am J Health Syst Pharm 56, 940 (1999).
  742. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol 73, 3595-3602 (1999).
  743. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C. Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. Biochemistry 38, 3447-3455 (1999).
  744. Mechoulam, R. Recent advantages in cannabinoid research. Forsch Komplementarmed 6 Suppl 3, 16-20 (1999).
  745. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20, 1286-1293 (1999).
  746. Zhang, Z. F. et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 8, 1071-1078 (1999).
  747. Rosenthal, M. S. & Kleber, H. D. Making sense of medical marijuana. Proc Assoc Am Physicians 111, 159-165 (1999).
  748. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469, 527-533 (1999).
  749. Leker, R. R., Shohami, E., Abramsky, O. & Ovadia, H. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 162, 114-119 (1999).
  750. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458, 400-404 (1999).
  751. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 72, 522- 528 (1999).
  752. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the

  753. serotonin transporter in human placenta. Am J Obstet Gynecol 181, 491-497 (1999).

  754. Gorter, R. W. Cancer cachexia and cannabinoids. Forsch Komplementarmed 6 Suppl 3, 21-22 (1999).
  755. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440, 266-274 (1999).
  756. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management in advanced cancer. Psychooncology 7, 346-358 (1998).
  757. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331, 15-19 (1998).
  758. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425, 419-425 (1998).
  759. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95, 8375-8380 (1998).
  760. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. Life Sci 63, PL197-PL204 (1998).
  761. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 436, 449-454 (1998).
  762. Barsky, S. H., Roth, M. D., Kleerup, E. C., Simmons, M. & Tashkin, D. P. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 90, 1198-1205 (1998).
  763. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41, 163-170 (1998).
  764. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9- tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436, 6-10 (1998).
  765. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179-185 (1998).
  766. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6, 204-214 (1998).
  767. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol Res 4, 191-199 (1998).
  768. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21, 353-356 (1998).
  769. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem 254, 634-642 (1998).
  770. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid

  771. amide hydrolase. Biochem Biophys Res Commun 248, 515-522 (1998).

  772. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 273, 32332-32339 (1998).
  773. Taylor, H. G. Analysis of the medical use of marijuana and its societal implications. J Am Pharm Assoc (Wash) 38, 220-227 (1998).
  774. Roth, M. D. et al. Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 157, 928-937 (1998).
  775. Calhoun, S. R., Galloway, G. P. & Smith, D. E. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 30, 187-196 (1998).
  776. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 239, 473-479 (1997).
  777. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum 24, 20-32 (1997).
  778. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 60, 1563-1573 (1997).
  779. Gallily, R. et al. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283, 918-924 (1997).
  780. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9- tetrahydrocannabinol and marijuana. Ann Intern Med 126, 791-798 (1997).
  781. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 3, 39-45 (1997).
  782. Baldwin, G. C. et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 156, 1606-1613 (1997).
  783. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 53, 207-214 (1997).
  784. Gonzalez-Rosales, F. & Walsh, D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage 14, 311-314 (1997).
  785. Berdyshev, E. V. et al. Influence of fatty acid ethanolamides and delta9- tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330, 231-240 (1997).
  786. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231, 217-221 (1997).
  787. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53, 35-41 (1997).
  788. Sanchez, C., Velasco, G. & Guzman, M. Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Res 767, 64-71 (1997).
  789. Shohami, E., Gallily, R., Mechoulam, R., Bass, R. & Ben-Hur, T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72,

  790. 169-177 (1997).

  791. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142, 278-287 (1997).
  792. De Petrocellis, L. et al. Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. Adv Exp Med Biol 433, 259-263 (1997).
  793. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322, 671-677 (1997).
  794. Axelrod, R. S. Antiemetic therapy. Compr Ther 23, 539-545 (1997).
  795. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler’s virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933 (1997).
  796. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30, 109-117 (1996).
  797. Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. Gen Pharmacol 27, 1141-1143 (1996).
  798. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2- arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun 227, 281-288 (1996).
  799. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser S 446, 1-317 (1996).
  800. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 39, 197-221 (1996).
  801. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 212, 123-126 (1996).
  802. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. Int J Immunopharmacol 18, 53-68 (1996).
  803. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol. Pharmacology 52, 271-282 (1996).
  804. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316, 977-984 (1996).
  805. Bass, R., Engelhard, D., Trembovler, V. & Shohami, E. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Infect Dis 173, 735-738 (1996).
  806. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N- 18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). Biochem

  807. Pharmacol 49, 855-858 (1995).

  808. Gilbert, C. J., Ohly, K. V., Rosner, G. & Peters, W. P. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 76, 2330-2337 (1995).
  809. Smart, T. Other therapies for wasting. GMHC Treat Issues 9(5), 7-8, 12 (1995).
  810. Fride, E. et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 272, 699-707 (1995).
  811. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. Pharmacol Biochem Behav 50, 141-146 (1995).
  812. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? Biochem Soc Trans 23, 418S (1995).
  813. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proc Soc Exp Biol Med 210, 64-76 (1995).
  814. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9- Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 209, 205-212 (1995).
  815. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15, 6552- 6561 (1995).
  816. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano- Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56, 2065-2072 (1995).
  817. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein expression in mouse peritoneal macrophages. Biochem Pharmacol 47, 2243-2252 (1994).
  818. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269, 22937-22940 (1994).
  819. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54, 1831-1844 (1994).
  820. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell Immunol 154, 99- 108 (1994).
  821. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. Int J Immunopharmacol 16, 593-603 (1994).
  822. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9- Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci 54, 1281-1289 (1994).
  823. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer patients. Cancer Surv 21, 99-115 (1994).

  824. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9- tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10, 14-18 (1994).
  825. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44, 1008-1015 (1993).
  826. Zheng, Z. M., Specter, S. & Friedman, H. Serum proteins affect the inhibition by delta-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse macrophages. Adv Exp Med Biol 335, 89-93 (1993).
  827. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 365, 61-65 (1993).
  828. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? Support Care Cancer 1, 298-304 (1993).
  829. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A. delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15, 371- 382 (1993).
  830. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267, 635-640 (1993).
  831. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9- tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post- translational events. J Pharmacol Exp Ther 267, 1558-1565 (1993).
  832. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214, 173-180 (1993).
  833. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44, 498-503 (1993).
  834. Nahas, G. & Latour, C. The human toxicity of marijuana. Med J Aust 156, 495-497 (1992).
  835. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). Drugs 43, 295-315 (1992).
  836. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic therapy. Clin Pharmacokinet 23, 147-160 (1992).
  837. Tchekmedyian, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr 16, 88S-92S (1992).
  838. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9- tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 14, 1445-1452 (1992).
  839. Bruera, E. Current pharmacological management of anorexia in cancer patients. Oncology (Huntingt) 6, 125-30; discussion 132, 137 (1992).
  840. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49 Suppl 2, 35-42 (1992).
  841. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89, 3825-3829 (1992).

  842. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106, 231-232 (1992).
  843. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9- tetrahydrocannabinol. J Leukoc Biol 50, 192-197 (1991).
  844. Plasse, T. F. et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40, 695-700 (1991).
  845. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13, 1091-1097 (1991).
  846. Gorter, R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology (Huntingt) 5, 13-17 (1991).
  847. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 288, 63-70 (1991).
  848. Cabral, G. A. & Vasquez, R. Effects of marijuana on macrophage function. Adv Exp Med Biol 288, 93-105 (1991).
  849. Lane, M. et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6, 352-359 (1991).
  850. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9- tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. Brain Res 560, 245-250 (1991).
  851. Specter, S., Lancz, G., Westrich, G. & Friedman, H. Combined immunosuppressive activities of delta-9-tetrahydrocannabinol and murine retrovirus. Adv Exp Med Biol 288, 135-141 (1991).
  852. Burstein, S. Cannabinoid induced changes in eicosanoid synthesis by mouse peritoneal cells. Adv Exp Med Biol 288, 107-112 (1991).
  853. Rowley, J. T. & Rowley, P. T. Tetrahydrocannabinol inhibits adenyl cyclase in human leukemia cells. Life Sci 46, 217-222 (1990).
  854. Tashkin, D. P. Pulmonary complications of smoked substance abuse. West J Med 152, 525-530 (1990).
  855. Johnson, B. A. Psychopharmacological effects of cannabis. Br J Hosp Med 43, 114- 6, 118 (1990).
  856. Tortorice, P. V. & O’Connell, M. B. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10, 129-145 (1990).
  857. Lane, M., Smith, F. E., Sullivan, R. A. & Plasse, T. F. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 13, 480-484 (1990).
  858. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 68, 304-313 (1990).
  859. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem Pharmacol 38, 3297-3304 (1989).
  860. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal

  861. propulsion and motility in rodents. J Pharmacol Exp Ther 249, 444-449 (1989).

  862. Grunberg, S. M. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 3, 216-221 (1989).
  863. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2- induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol 10, 485-488 (1988).
  864. Trissel, L. A. & Flora, K. P. Stability studies: five years later. Am J Hosp Pharm 45, 1569-1571 (1988).
  865. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244, 1157-1163 (1988).
  866. Nabilone and other antiemetics for cancer patients. Med Lett Drugs Ther 29, 2-4 (1988).
  867. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6, 243-246 (1988).
  868. Manzo, M. Dronabinol and nabilone ease cancer chemotherapy. Nursing 18, 81 (1988).
  869. Cunningham, D. et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24, 685-689 (1988).
  870. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. NIDA Res Monogr 79, 148-157 (1987).
  871. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC carbamate. Alcohol Drug Res 7, 517-523 (1987).
  872. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 34, 136-149 (1987).
  873. Chan, H. S., Correia, J. A. & MacLeod, S. M. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79, 946-952 (1987).
  874. Yahya, M. D. & Watson, R. R. Immunomodulation by morphine and marijuana. Life Sci 41, 2503-2510 (1987).
  875. Niiranen, A. & Mattson, K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 10, 325-329 (1987).
  876. Hanasono, G. K., Sullivan, H. R., Gries, C. L., Jordan, W. H. & Emmerson, J. L. A species comparison of the toxicity of nabilone, a new synthetic cannabinoid. Fundam Appl Toxicol 9, 185-197 (1987).
  877. Roffman, R. A. Stress inoculation training in the control of THC toxicities. Int J Addict 21, 883-896 (1986).
  878. Pomeroy, M., Fennelly, J. J. & Towers, M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17, 285-288 (1986).
  879. Dalzell, A. M., Bartlett, H. & Lilleyman, J. S. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 61, 502-505 (1986).
  880. Crawford, S. M. & Buckman, R. Nabilone and metoclopramide in the treatment of

  881. nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor

  882. Pharmacother 3, 39-42 (1986).

  883. Murray, J. B. Marijuana’s effects on human cognitive functions, psychomotor functions, and personality. J Gen Psychol 113, 23-55 (1986).
  884. Donald, P. J. Marijuana smoking--possible cause of head and neck carcinoma in young patients. Otolaryngol Head Neck Surg 94, 517-521 (1986).
  885. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol 8, 741- 745 (1986).
  886. Niederle, N., Schutte, J. & Schmidt, C. G. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64, 362-365 (1986).
  887. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 10, 143-166 (1985).
  888. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient-- the UCLA study. Part II: Patient drug preference. Am J Clin Oncol 8, 142-147 (1985).
  889. Synthetic marijuana for nausea and vomiting due to cancer chemotherapy. Med Lett Drugs Ther 27, 97-98 (1985).
  890. Ward, A. & Holmes, B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 30, 127-144 (1985).
  891. Perlin, E. et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci 74, 171-174 (1985).
  892. Landauer, M. R., Balster, R. L. & Harris, L. S. Attenuation of cyclophosphamide- induced taste aversions in mice by prochlorperazine, delta 9-tetrahydrocannabinol, nabilone and levonantradol. Pharmacol Biochem Behav 23, 259-266 (1985).
  893. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9- tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69, 109-112 (1985).
  894. Niiranen, A. & Mattson, K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8, 336-340 (1985).
  895. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic drug- induced vomiting]. Klin Wochenschr 62, 441-445 (1984).
  896. Dow, G. J., Meyers, F. H., Stanton, W. & Devine, M. L. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clin Pharm 3(1), 14 (1984).
  897. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. Arch Intern Med 144, 1029-1033 (1984).
  898. Fiore, J. J. & Gralla, R. J. Pharmacologic treatment of chemotherapy-induced nausea and vomiting. Cancer Invest 2, 351-361 (1984).
  899. Niamatali, C., Fallon, S. D. & Egan, E. L. Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis. Ir Med J 77, 276- 277 (1984).
  900. listed], [. N. A. Nabilone and high-dose metoclopramide: anti-emetics for cancer

  901. chemotherapy. Drug Ther Bull 22, 9-11 (1984).

  902. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9- tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68, 1427-1431 (1984).
  903. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol. Chemical synthesis and biological testing and evaluation as a potentially site- specific anti-tumor agent. Sci Sin [B] 27, 1048-1058 (1984).
  904. Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and vomiting. Cancer 54, 2642-2648 (1984).
  905. Gralla, R. J. et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9- tetrahydrocannabinol. Cancer Treat Rep 68, 163-172 (1984).
  906. Bakowski, M. T. Advances in anti-emetic therapy. Cancer Treat Rev 11, 237-256 (1984).
  907. George, M., Pejovic, M. H., Thuaire, M., Kramar, A. & Wolff, J. P. [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin]. Biomed Pharmacother 37, 24-27 (1983).
  908. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25 Suppl 1, 1-7 (1983).
  909. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99, 106-114 (1983).
  910. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients. JAMA 249, 1469-1472 (1983).
  911. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in patients with testicular cancer. Lancet 2(8359), 1144 (1983).
  912. Ahmedzai, S., Carlyle, D. L., Calder, I. T. & Moran, F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48, 657-663 (1983).
  913. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use]. Fortschr Med 100, 343-346 (1982).
  914. Cone, L. A., Greene, D. S. & Helm, N. A. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer Treat Rev 9 Suppl B, 63-70 (1982).
  915. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 3-9 (1982).
  916. Stark, P. The pharmacologic profile of nabilone: a new antiemetic agent. Cancer Treat Rev 9 Suppl B, 11-16 (1982).
  917. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer Institute program in Wisconsin. Wis Med J 81, 24 (1982).
  918. Stark, P. Study design for the evaluation of the efficacy and safety of nabilone. Cancer Treat Rev 9 Suppl B, 35-37 (1982).
  919. Lemberger, L. et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9 Suppl B, 17-23 (1982).
  920. Einhorn, L. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 55-61 (1982).
  921. Levitt, M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea

  922. and vomiting in cancer patients. Cancer Treat Rev 9 Suppl B, 49-53 (1982).

  923. Stark, P. Nabilone and cancer chemotherapy. Ann Intern Med 96(1), 122 (1982).
  924. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother Pharmacol 9, 61-64 (1982).
  925. Wada, J. K. et al. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 39-44 (1982).
  926. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50, 636-645 (1982).
  927. Weddington, W. W. J., Miller, N. J. & Sweet, D. L. Anticipatory nausea and vomiting associated with cancer chemotherapy. N Engl J Med 307(13), 825-826 (1982).
  928. Jones, S. E., Durant, J. R., Greco, F. A. & Robertone, A. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 9 Suppl B, 45-48 (1982).
  929. Johansson, R., Kilkku, P. & Groenroos, M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 25-33 (1982).
  930. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. J Clin Pharmacol 21, 128S-132S (1981).
  931. Scigliano, J. A. THC therapeutic research by independent and state-sponsored investigators: a historical review. J Clin Pharmacol 21, 113S-121S (1981).
  932. Procedure for obtaining THC for cancer patients. JAMA 246, 15-19 (1981).
  933. Aapro, M. S. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Ariz Med 38, 843-845 (1981).
  934. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 21, 103S- 109S (1981).
  935. Einhorn, L. H., Nagy, C., Furnas, B. & Williams, S. D. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21, 64S- 69S (1981).
  936. Montour, J. L., Dutz, W. & Harris, L. S. Modification of radiation carcinogenesis by marihuana. Cancer 47, 1279-1285 (1981).
  937. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). J Clin Pharmacol 21, 122S-127S (1981).
  938. Gunby, P. Many cancer patients receiving THC as antiemetic. JAMA 245, 1515, 1518 (1981).
  939. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC dispensing. Pharm Times 47, 32-36 (1981).
  940. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic. Am J Hosp Pharm 38, 639-646 (1981).
  941. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9- tetrahydrocannabinol in clinical oncology. JAMA 245, 2047-2051 (1981).

  942. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9- Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21, 70S-75S (1981).
  943. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 21, 11S-22S (1981).
  944. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21, 214S-223S (1981).
  945. Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. J Clin Pharmacol 21, 57S- 59S (1981).
  946. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47, 1746-1751 (1981).
  947. Cocchetto, D. M., Cook, L. F. & Cato, A. E. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. Drug Intell Clin Pharm 15, 867-875 (1981).
  948. Colls, B. M., Ferry, D. G., Gray, A. J., Harvey, V. J. & McQueen, E. G. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 91, 449- 451 (1980).
  949. Earhart, R. H. & Buchanan-Davidson, D. J. Tetrahydrocannabinol as an antiemetic for cancer patients. Wis Med J 79, 47-48 (1980).
  950. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and vomiting in cancer patients. J Med Assoc Ga 69, 919-920 (1980).
  951. Marihuana for nausea and vomiting due to cancer chemotherapy. Med Lett Drugs Ther 22, 41-43 (1980).
  952. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients? Opinion 2. CA Cancer J Clin 30, 283-285 (1980).
  953. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. CA Cancer J Clin 30, 278-282 (1980).
  954. Seipp, C. A., Chang, A. E., Shiling, D. J. & Rosenberg, S. A. In search of an effective antiemetic: a nusring staff participates in marijuana research. Cancer Nurs 3, 271-276 (1980).
  955. Levy, J. A. & Heppner, G. H. Immunosuppression by marihuana and its cannabinoid constituents. J Immunopharmacol 2, 159-177 (1980).
  956. Steele, N., Gralla, R. J., Braun, D. W. J. & Young, C. W. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy- induced emesis. Cancer Treat Rep 64, 219-224 (1980).
  957. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243, 1241-1243 (1980).
  958. Colls, B. M. Cannabis and cancer chemotherapy. Lancet 1, 1187-1188 (1980).
  959. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9- tetrahydrocannabinol and prochlorperazine. N Engl J Med 302, 135-138 (1980).

  960. Williams, C. J., Bolton, A., de Pemberton, R. & Whitehouse, J. M. Antiemetics for patients treated with antitumor chemotherapy. Cancer Clin Trials 3, 363-367 (1980).
  961. London, S. W., McCarthy, L. E. & Borison, H. L. Suppression of cancer chemotherapy-induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc Soc Exp Biol Med 160, 437-440 (1979).
  962. Herman, T. S. et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300, 1295-1297 (1979).
  963. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91, 825-830 (1979).
  964. Chang, A. E. et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91, 819-824 (1979).

  965. 944. Bedell, S. E. Cannabis and cancer chemotherapy. Ann Intern Med 90(2), 276 (1979).

  966. Gylys, J. A., Doran, K. M. & Buyniski, J. P. Antagonism of cisplatin induced emesis in the dog. Res Commun Chem Pathol Pharmacol 23, 61-68 (1979).
  967. Ekert, H., Waters, K. D., Jurk, I. H., Mobilia, J. & Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 2, 657-659 (1979).
  968. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis. Naturwissenschaften 65, 174-179 (1978).
  969. Toro-Goyco, E., Rodreguez, M. B. & Preston, A. M. On the action of delta 9- tetrahydrocannabinol as an inhibitor of sodium- and potassium-dependent adenosine triphosphatase. Mol Pharmacol 14, 130-137 (1978).
  970. Staquet, M., Gantt, C. & Machin, D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23, 397-401 (1978).
  971. Herman, T. S. et al. Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine 27, 331-334 (1977).
  972. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of cortiocosteroidogenesis by delta-9-tetrahydrocannabinol. Endocrinology 101, 1815-1820 (1977).
  973. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem Biophys 2, 51-54 (1977).
  974. Nichols, D. E., Mason, D. L. & Jacobsen, L. B. Allylbenzene analogs of delta9- tetrahydrocannabinol as tumor growth inhibitors. Life Sci 21, 1245-1248 (1977).
  975. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis by cannabinoids. Cancer Res 36, 95-100 (1976).
  976. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta9- tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst 56, 655-658 (1976).
  977. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18, 84-89 (1975).
  978. Patel, A. R. & Gori, G. B. Preparation and monitoring of marijuana smoke condensate samples. Bull Narc 27, 47-54 (1975).
  979. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55, 597-602 (1975).
  980. Sallan, S. E., Zinberg, N. E. & Frei, E. Antiemetic effect of delta-9- tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293, 795-797 (1975). 960.
  981. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9- tetrahydrocannabinol. J Clin Pharmacol 15, 139-143 (1975).

  982.  

  983.